Impact BioMedical (IBO) said Monday it agreed to merge with Hong Kong-based pharmaceutical group Dr. Ashleys that will result in a newly formed entity under "Dr Ashleys Limited."
Shares of Impact jumped 350%, with intraday trading volume of over 379 million against a daily average of about 6.81 million.
Cidara Therapeutics (CDTX) shares doubled after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults met its primary and all secondary efficacy endpoints for all dose groups.
RBC raised its price target on the stock to $75 from $35 while maintaining its outperform rating.
More than 5.25 million shares of Cidara traded intraday, compared with a daily average of about 171,000.
SpartanNash (SPTN) said it agreed to be acquired by C&S Wholesale Grocers for $26.90 per share for a total purchase price of $1.77 billion.
Shares of SpartanNash soared 50% as trading volume surged to over 7.1 million shares from a daily average of roughly 323,000.
Price: 1.70, Change: +1.34, Percent Change: +369.51
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。